| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -2.0 | -1.6 |
| EPS (diluted, $ a share) | $-1.72 | $-16.92 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: BJDX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Bluejay Diagnostics, Inc.: key numbers
- Share price
- $2.29Close, Nov 16
- Market cap
- $2.56M
- Shares outstanding
- 1.12MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Bluejay Diagnostics, Inc.
All →Bluejay Diagnostics Business Update
Bluejay Diagnostics provided a corporate update for Q3 2026, highlighting the completion of enrollment for its SYMON-II clinical study and the establishment of an alternative manufacturing site ahead of schedule. The company reported a cash balance of $7.38 million and targets an FDA 510(k) submission for its Symphony IL-6 platform in the first half of 2027.
Bluejay Diagnostics Reverse Stock Split
Bluejay Diagnostics implemented a 1-for-4 reverse stock split of its common stock, effective November 3, 2026. The split reduces the number of outstanding shares from approximately 4.47 million to 1.12 million to maintain compliance with Nasdaq listing requirements. Trading will continue under the ticker 'BJDX' with a new CUSIP number.
Bluejay Diagnostics Business Update
Bluejay Diagnostics achieved a critical contractual milestone under its license agreement with Toray Industries by establishing a manufacturing site for its Symphony cartridges at SanyoSeiko Co. in Japan. This milestone was reached ahead of the October 23, 2026 deadline and is part of a broader strategy to build a resilient supply chain alongside its U.S. manufacturing partner, ALURIS Sciences.
- Counterparty
- Toray Industries, Inc.
Bluejay Diagnostics Clinical Trial Data
Bluejay Diagnostics announced baseline clinical characteristics from its SYMON-II clinical validation study, which is evaluating the Symphony IL-6 Test for mortality risk in sepsis patients. The study includes 777 evaluable patients with an 18% mortality rate, providing a diverse dataset to support the company's planned regulatory submission. The data showed that non-survivors had higher baseline illness severity, with septic shock present in 56.4% of that group.